Evidence map›Paper›PMID 37715096›Full record

Observational studyJournal of general internal medicine2023

The Influence of Social Determinants on Receiving Outpatient Treatment with Monoclonal Antibodies, Disease Risk, and Effectiveness for COVID-19.

Nalini Ambrose, Alpesh Amin, Brian Anderson, Monica Bertagnolli, Francis Campion, Dan Chow, Risa Danan, Lauren D'Arinzo, Ashley Drews, Karl Erlandson and 23 more

Open access · bronzeAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of general internal medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 9 institutions in 1 country.

Nalini AmbroseThe MITRE Corporation, Bedford, MA, USA.
Alpesh AminDepartment of Medicine, University of California, Irvine, CA, USA.
Brian AndersonThe MITRE Corporation, Bedford, MA, USA.
Monica BertagnolliDivision of Surgical Oncology, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Francis CampionThe MITRE Corporation, Bedford, MA, USA. fcampion@mitre.org.ORCID 0000-0002-0757-9305
Dan ChowDepartment of Radiological Sciences, University of California, Irvine, CA, USA.
Risa DananThe MITRE Corporation, Bedford, MA, USA.
Lauren D'ArinzoThe MITRE Corporation, Bedford, MA, USA.
Ashley DrewsDivision of Infectious Diseases, Department of Medicine, Houston Methodist, Houston, TX, USA.
Karl ErlandsonBiomedical Advanced Research and Development Authority (BARDA), Administration for Strategic Preparedness and Response, US Department of Health and Human Services, Washington, DC, USA.
Kristin FitzgeraldThe MITRE Corporation, Bedford, MA, USA.
Fraser GasparThe MITRE Corporation, Bedford, MA, USA.
Carlene GongBooz Allen Hamilton in Support of BARDA, Washington, DC, USA.
George HannaTunnell Government Services in Support of BARDA, Princeton, NJ, USA.
Heather HawleyThe MITRE Corporation, Bedford, MA, USA.
Stephen JonesCenter for Health Data Science and Analytics, Houston Methodist, Houston, TX, USA.
Bert LopansriDivision of Infectious Diseases and Clinical Epidemiology, Intermountain Health, Murray, UT, USA.
Ty MullenThe MITRE Corporation, Bedford, MA, USA.
James MusserLaboratory of Molecular and Translational Human Infectious Disease Research, Center for Infectious Diseases, Department of Pathology and Genomic Medicine, Houston Methodist Research Institute and Houston Methodist Hospital, Houston, TX, USA.
John O'HoroCenter for Individualized Medicine-Mayo Clinic Research, Rochester, MN, USA.
Steven PiantadosiDepartment of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Bobbi PrittCenter for Individualized Medicine-Mayo Clinic Research, Rochester, MN, USA.
Raymund RazonableCenter for Individualized Medicine-Mayo Clinic Research, Rochester, MN, USA.
Shyam ReleThe MITRE Corporation, Bedford, MA, USA.
Seth RobertsThe MITRE Corporation, Bedford, MA, USA.
Suzanne SandmeyerDepartment of Biological Chemistry, School of Medicine, University of California, Irvine, CA, USA.
David SteinThe MITRE Corporation, Bedford, MA, USA.
Jerez TeThe MITRE Corporation, Bedford, MA, USA.
Farhaan VahidyCenter for Health Data Science and Analytics, Houston Methodist, Houston, TX, USA.
Brandon WebbDivision of Infectious Diseases and Clinical Epidemiology, Intermountain Health, Murray, UT, USA.
Nathan WelchThe MITRE Corporation, Bedford, MA, USA.
Alexander WoodThe MITRE Corporation, Bedford, MA, USA.
Jennifer YttriThe MITRE Corporation, Bedford, MA, USA.
Mitre (United States) · USHouston Methodist · USMayo Clinic · USUniversity of California, Irvine · USBrigham and Women's Hospital · USIntermountain Healthcare · USBiomedical Advanced Research and Development Authority · USBooz Allen Hamilton (United States) · USManagement Support Technology (United States) · US

Funding

Administration for Strategic Preparedness and Response Contract Number 75FCMC18D0047 Task Order 75A50121F80012
6 · The paper itself

Abstract

backgroundLimited research has studied the influence of social determinants of health (SDoH) on the receipt, disease risk, and subsequent effectiveness of neutralizing monoclonal antibodies (nMAbs) for outpatient treatment of COVID-19.

objectiveTo examine the influence of SDoH variables on receiving nMAb treatments and the risk of a poor COVID-19 outcome, as well as nMAb treatment effectiveness across SDoH subgroups.

designRetrospective observational study utilizing electronic health record data from four health systems. SDoH variables analyzed included race, ethnicity, insurance, marital status, Area Deprivation Index, and population density.

participantsCOVID-19 patients who met at least one emergency use authorization criterion for nMAb treatment. MAIN MEASURE: We used binary logistic regression to examine the influence of SDoH variables on receiving nMAb treatments and risk of a poor outcome from COVID-19 and marginal structural models to study treatment effectiveness.

resultsThe study population included 25,241 (15.1%) nMAb-treated and 141,942 (84.9%) non-treated patients. Black or African American patients were less likely to receive treatment than white non-Hispanic patients (adjusted odds ratio (OR) = 0.86; 95% CI = 0.82-0.91). Patients who were on Medicaid, divorced or widowed, living in rural areas, or living in areas with the highest Area Deprivation Index (most vulnerable) had lower odds of receiving nMAb treatment, but a higher risk of a poor outcome. For example, compared to patients on private insurance, Medicaid patients had 0.89 (95% CI = 0.84-0.93) times the odds of receiving nMAb treatment, but 1.18 (95% CI = 1.13-1.24) times the odds of a poor COVID-19 outcome. Age, comorbidities, and COVID-19 vaccination status had a stronger influence on risk of a poor outcome than SDoH variables. nMAb treatment benefited all SDoH subgroups with lower rates of 14-day hospitalization and 30-day mortality.

conclusionDisparities existed in receiving nMAbs within SDoH subgroups despite the benefit of treatment across subgroups.

Indexed as

COVID-19COVID-19 VaccinesAntibodies, MonoclonalHumansOutpatientsSocial Determinants of HealthUnited StatesAntibodies, MonoclonalCOVID-19 VaccinesCOVID-19disease riskeffectivenessmonoclonal antibodiessocial determinants of healthtreatment

Identifiers

PMID37715096
PMCPMC10713505
OpenAlexW4386764879

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.